A Publication of Global Scientific Forum
Card image

Original Article

Branded versus Generic (Branded-Generic) Medicines-For Whose Benefit?

*Corresponding Author:
Sonali P Suryawanshi
Assistant Professor, Department of Pharmacology, Bharati Vidyapeeth Deemed University Medical College, Katraj, Dhankawadi, Pune-411 043, Maharashtra, India.
E-mail: docssurya@gmail.com

Citation: Suryawanshi SP, Totlani PS, Sahasrabudhe RA. Branded Versus Generic (Branded-Generic) Medicines-For Whose Benefit?. J Basic Clin Pharm 2017;8:158-161.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.


Introduction: Cost of medicines is a major concern today. Generic drugs provide major saving opportunity in healthcare expenditure since they usually have lower price. However, physicians and patients are apprehensive regarding their quality, although they are bio-equivalents of the innovator products. The present study therefore compares the price structure and antibacterial activity of the branded products and their branded-generic counterparts. Methodology: Commonly used branded and branded-generic versions of three oral cephalosporins available in the pharmacy were studied. Health cost was compared by comparing Maximum retail price (MRP) and price-to-retailers (PTR) and trade margins. The antibacterial activity of the pairs was assessed by “Kirby Bauer” disk diffusion method, by comparing the zones of inhibition. Results: The retailer margin for the three branded medicines was in the range of 17-25% but for their branded-generic versions, it was huge, in the range of 73-130%. By switching over to branded generic medicines cost benefit to pharmacist ranged from 270% to 422% but for patients it was only 5%-48.3%. There was no difference in the zones of inhibition obtained for the branded generic and the corresponding branded drugs, indicating equal effectiveness. Conclusion: Branded generic cephalosporins, equi-effective as the branded versions, with lesser cost to the patient, can be used clinically. However, cost benefit to the patients, being hyped in the media, is very meager compared to the profit margins for the retailers. Steps are needed to ensure that the cost benefit with the use of generics reaches the patients in appropriate amounts.


Branded-branded generics, cost of medicines, antimicrobial activity


India is the 4th largest producer and 10th largest exporter of drugs in the world. In spite of Government provision for health care budget, major proportion Indian population does not have access to even essential medicines.[1] With the sky-rocketing healthcare costs, the interest in generic drugs has increased all over the world, amongst rich or poor. Generic drugs enable major savings in healthcare expenditure since they are usually substantially lower in price than the innovator brands. [2] In India, in view of poor accessibility and affordability of people, it is absolutely essential that the generic drugs should be made available to minimize the cost of treatment. Reported production and use of generic drugs had jumped from 49% of the global drug market in 2000 to 78% in 2010.[3] In India, many pharmaceutical companies manufacture a product under both types, i.e., the branded product which they advertise and push through doctors and branded-generics which they expect to be sold over the counter by retailers. Generic drugs in simple terms are the copy of the branded ones having same ingredients, same dosage, same indications and exactly same pharmacological effects, as the manufacturing companies use the same active ingredients in both type of formulations. However, physicians are apprehensive regarding the quality of generic drugs [4] Consumer awareness for the generics, variety of trade names available in the market, and price variation is also very limited. Though in certain parts of India, government authorities recommend prescribing drugs by their generic names, drugs continue to be prescribed by the brand names and Doctors as well as patients do not want pharmacists to change the trade name written by doctor, despite the possible cost benefit. The present study was therefore undertaken to compare the price structure and antibacterial activity of the branded products and their branded-generic counterparts after the institutional ethical clearance. The same study had also been selected for ICMR–STS 2016-17.


1. To compare the Price-to-patient (MRP - Maximum Retail Price) and Price-to retailers (PTR) and Trade margin of “branded” and “branded-generic” equivalents of some commonly used oral cephalosporins available in the tertiary care hospital pharmacy.

2. To compare the antibacterial activity of these formulations of cephalosporins.


Three commonly used oral cephalosporins available as branded and branded-generic versions were selected. Basic information of the brands used was recorded from the formulation packs [Table 1].

Cephalosporin Code Batch No Mfg date Expiry
Brand Name & Manufacturer
Cephalexin B1 2706924 6/2015 2/2017 Sporidex 250
Sun pharma
BG1 B651155 11/2015 6/2017 Cephadex 250
Cefuroxime Axetil B2 5133176 12/2015 11/2017 Zocef 500
BG2 WBT-5240B 10/2015 9/2017 Bullcef 500
Ultra-Drugs Pvt. Ltd.
Cefixime  B3 EI 51546 11/2015 10/2017 Ziprax-200 DT
BG3 TX-7718 05/2015 4/2017 Cefixar-200 DT
Legen healthcare

Table 1: Details of the drug products selected for comparative analysis.

Difference in cost

Medicines are available to patients at the MRP mentioned on the package of medicine. PTR is the price at which wholesaler (distributor) sells the product to the retailer and was noted from the purchase rate vouchers. Price-to-patient and price-to-retailers was analyzed for all the “pairs” of cephalosporins and Trade Margin for the retailer was calculated by using the formula:


We also calculated the percentage increase in trade margin for the retailer and % cost benefit to the patient on switching to generic products.

Antibacterial activity

The antibacterial activity of all the selected formulations of the 3 cephalosporins against Escherichia coli and Staph aureus species isolated from different clinical samples was tested by “Kirby Bauer” disk diffusion method according to the ‘Clinical and Laboratory Standards Institute’ (CLSI) guidelines.[5]

The present study was performed with 30 μg Cephalosporin containing discs. The 3 Cephalosporins were coded as 1, 2, 3 with suffix B for branded and BG for branded generic drug in each pair. The 30 μg Cephalosporin discs of different brands were prepared by serial dilution using phosphate buffer 6 or 7 for the available strength of tablets or capsules. The discs were soaked for 24 hours and refrigerated. Antibacterial activity was tested the next day. Zones of inhibition was measured in mm after 24 hours of incubation by CLSI / Eucast reference for Disk diffusion (Kirby-Bauer) method.[6,7]

Data analysis

Cost aspect was analyzed by comparing the PTR, MRP, Trade margin and percentage difference in trade margin for the retailer and cost benefit to the patient on switching to the generic brand. For measurement of antibacterial activity, zone of inhibition was measured in millimeter (mm).

Observations and results

The samples of the 6 formulations obtained were stored according to the manufacturer’s packaging instructions and kept there until testing. The microbiologist who conducted the study was kept blinded. The description of the codes for all the brands and the details of drug products selected for this study are given in Tables 1 and 2.

Drug Name PTR MRP Trade
On switching to branded generics
increase in  trade margin % increase in trade margin Cost benefit to the patient % Cost benefit to Patient
1 Cephalexin (B1 84.8 106 25  105.5 422% 45.2 42.6%
Cephalexin (BG1) 26.40 60.8 130.5
2 Cefuroxime Axetil (B2) 460 557 21.08 58.92 270% 269 48.3%
Cefuroxime Axetil (BG2) 160 288 80
3 Cefixime DT (B3) 81 95 17.28 55.79 322% 5 5%
Cefixime DT (BG3) 52 90 73.07

Table 2: Cost benefit to pharmacist and patient.

The above table shows the basic details of the procured branded and branded generic cephalosporins. All the drugs studied during May- June 2016 were manufactured in 2015 and had expiry in 2017.

Assessment of cost benefit

Table 2 shows the cost benefit to pharmacist (Trade margin) and patients with the use of selected branded generic drugs. It is seen that the trade margin which is 25% with branded cephalexin increased to 130.5% with branded generic cephalexin–effectively increasing the profit to the pharmacist by 422%. With the difference in the MRPs of the two products, cost benefit to the patients is 42.6% which is just 10% of the benefit to the retailer Thus, the study reveals that there are huge mark-ups for retailers on branded-generic medicines because of significantly lower PTR. The retailer margin for three branded medicines studied was in the range of 17-25%, but for their branded-generics version, it was in the range of 73-130% [Table 2]. By switching over to branded generic medicines cost benefit to pharmacist increased from 270% to 422%. Patient benefit depends on the difference in MRP. For the three drugs studied, patient benefit was only 5%-48.3%.

Assessment of antibacterial activity

We have compared the antibacterial activity of branded and branded generic formulations of 3 oral cephalosporins using disk diffusion method (Kirby-Bauer method). Each tablet in the respective pair had the same strength [Table 1]. The results of the study in terms of diameters of zones of inhibition produced by the different brands of cephalosporin tablets against the tested bacterial strains are given is given in Table 3. Photographs of the plates with the zones of inhibition are given in Figure 1. According to Table 3, amongst the three pairs of oral cephalosporins, the zones of inhibition did not differ between the branded and branded generic formulations. In fact, the zones of inhibition for the branded generics were slightly larger than those for the corresponding branded formulations.

Pair Sr.
Drug Name Zone of Inhibition (mm) Recommended Zones of inhibition (mm)
E. coliATCC Staph ATCC E. coli S. aureus
1 Cephalexin (B1) 18 mm 25 mm 15-21 29-37
Cephalexin  (BG1) 21mm 33mm
2 Cefuroxime Axetil (B2) 15mm 15mm 20-26 27-34
Cefuroxime Axetil (BG2) 20mm 15mm
3 Cefixime DT (B3) 20mm 10mm 23-27  
Cefixime DT (BG3) 21mm 15mm

Table 3: Zones of Inhibition of different brands of oral cephalosporin.


Figure 1: Zone of Inhibition of different Pairs of oral cephalosporin


The Original concept of Generics distinguishes these products form the ‘patented’ or ‘innovator’‘ products marketed by a company who has invested a lot of time, money and effort on the research. Once out of patent, the drug can be manufactured by other companies who have not invested in it at the research level and hence their brands can be available at a lesser cost to the patients. In low and middle income countries, originator brand medicines generally cost substantially more than their generic equivalents. Generic drugs provide the opportunity for major savings in healthcare expenditure.[2] In India the concept has a completely different connotation. Branded does not mean innovator patented products, but brands on which the company spends a lot for marketing, against the generics which are sold by giving huge incentive to the retailers.

Generics are supposed to be marketed and prescribed by the generic name of the drug. However, physicians are apprehensive regarding the quality of generic drugs.[4] That has led to the emergence of the so called ‘branded generics’, wherein the same reputed companies started manufacturing a product under both types, i.e., the branded product which they advertise and push through doctors and branded-generics which they expect to be pushed over the counter by retailers.

This is one of the first studies in India conducted systematically to compare difference in health care cost and antimicrobial efficacy of three oral cephalosporins available as branded and branded generic products. Efforts were made to procure these products having close manufacturing and expiry dates [Table 1].

Findings of the study revealed that though these branded generics are available to the patients at a somewhat lower cost than the corresponding branded formulations, this cost benefit is negligible as compared to the tremendously higher trade margins they offer to the retailers, who therefore willingly promote the sale of such (branded generic) products.

Other studies in India comparing different generic medicines to their branded counterparts also show that price-to-patient for the branded-generic version was not much less than to its branded counterpart; the price difference being only 71-100% of the branded formulation.[8,9]

Since there is not a substantial difference in the MRPs of these products, this higher trade margin is possible because of the very low PTR for the branded generics. PTR reflects the manufacturing cost of the product. This naturally leads to a question about the quality of generic drugs, supposedly produced at lower production cost? This justifies the apprehension about their quality in the minds of the clinicians and patients. There exists a widespread belief among people and dispensing chemists that a branded product is better in terms of quality and safety than the generic.[10,11]

Many reports comparing the effectiveness of branded generics and their branded counterparts are available. Many studies are conducted to test the therapeutic bio-equivalence of generic drugs even prior to marketing and there are number of published studies assuring the safety and efficacy of these generic drugs.[12-14] There are also many studies reporting that generic antibiotics behave differently from brand products against pathogenic microorganisms.[15,16] Doubts have also been raised about the efficacy of generic antibiotics, based on complaints from the medical community reported in the literature and at international meetings.[17] Farzana et al. have also reported comparable values of Minimum Inhibitory Concentrations for the local and multinational brands of 1st, 2nd and 3rd generation cephalosporins against clinical isolates of S. aureus.[18] A study carried out in Pakistan, showed no difference of in-vitro antibacterial activity of Ceftriaxone, even for the brand having the lowest MRP.[19] Another study by Bashir et al. reported that the multinational brands of Cephradine had better zones of inhibition than local Pharmaceutical companies. However, the difference was not statistically significant.[20]

Our study has shown that the branded and branded generic pairs of the same antibiotic had equal antimicrobial activity when tested in vitro. Comparable antimicrobial activity in vitro may however, get compromised by in adequate bioavailability of the formulation, resulting in inadequate antimicrobial activity in vivo. This aspect of comparison has not been addressed in our study. This limitation of our study needs to be taken care of by further studies. Such robust proof generated about equal effectiveness of these and other such pairs would make these products available at whatever cost benefit they offer to the patients. The other important point highlighted from our study and many others [18,19] is the tremendous difference in cost benefit to the retailers as compared to that for the patients. This demands that appropriate steps be taken to ensure that the cost benefit with the use of generics reaches the patients in appropriate amounts. Measures like defining the relative MRPs for branded and branded generic formulations of the same drug can be a step in this direction.


Our study revealed that the 3 branded and branded generic cephalosporins were equieffective in vitro. More elaborate studies would be needed to establish equal efficacy in vivo.

Measures are needed to ensure that the cost benefit does not remain restricted to the retailers and is also available to the patients in appropriate proportion.


journal-of-basic-and-clinical-pharmacy Journal of Basic and Clinical Pharmacy, a publication of Global Scientific Research Forum, is a peer-reviewed online journal with Quarterly print on demand compilation of issues published.
Submit your Manuscript

© Journal of Basic and Clinical Pharmacy
Online since 10 September, 2012 -